Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein
Journal of Virology · 2025
DOI: 10.1128/jvi.02268-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Cynthia A Pise-Masison und 11 weiteren Autor:innen. Beteiligte Einrichtung: Animal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes …. Hauptthemen laut MEDLINE: Human T-lymphotropic virus 1, Antibody-Dependent Cell Cytotoxicity, Viral Envelope Proteins, Antibodies, Viral. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | National Institutes of Health (NIH).
Abstract (Originalsprache)
An estimated 10–20 million people worldwide are infected with the deltaretrovirus human T-cell leukemia virus type 1 (HTLV-1). Although most infected individuals remain asymptomatic, some progress to develop the fatal and debilitating disease adult T-cell leukemia/lymphoma (ATLL) or HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) or develop a plethora of other inflammatory disorders. In addition, HTLV-1 infection is associated with immunosuppression and a shorter lifespan. Although a protective role for neutralizing antibodies has been suggested, the role of non-neutralizing antibody-dependent cell-mediated cytotoxicity (ADCC) remains unclear, largely because an assay to measure this response has not been established. Here, we developed a high-throughput flow cytometry-based assay system to measure HTLV-1 envelope-specific ADCC. We used a natural killer cell-resistant T-lymphoblastoid cell line stably expressing the green fluorescent protein GFP to construct a target cell line expressing HTLV-1 envelope protein and using monoclonal antibodies and plasma samples from HTLV-infected or uninfected individuals, validating the specificity and sensitivity of the assay. We detected high ADCC activity in samples from HTLV-1-infected humans. In the plasma of experimentally infected macaques, ADCC activity was measured and a correlation between ADCC activity and HTLV-1 envelope antibody titers was observed. Further, we observed a significant increase in ADCC titer over time; as HTLV-1 infection persists, a higher ADCC response is generated, potentially influencing disease outcome. ADCC titer in HTLV-1-infected macaques also positively correlated with FLT3LG, IL-17F, CD4 + T cells, and lymphocytes but negatively correlated with monocyte frequency and classical monocyte frequency. In conclusion, these findings detail the generation of a cell line that enabled development of an HTLV-specific ADCC assay, which can be employed in large clinical studies as well as research involving humans or non-human primates. IMPORTANCE This approach measures human T-cell leukemia virus (HTLV)-specific envelope antibody-dependent cell-mediated cytotoxicity responses, provides a critical tool to investigate the role of envelope-specific binding antibodies in the immune control of HTLV infection and pathogenesis, and may help guide the development of both therapeutic and preventative vaccine approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Animal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Laboratory of Biochemistry and Genetics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- Translational Nanobiology Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Cynthia A Pise-Masison, Mohammad Arif Rahman, Genoveffa Franchini
Förderung
- HHS | National Institutes of Health (NIH)
Zitieren
APA
Pise-Masison, C. A., Rahman, M. A., Masison, D. C., Gutowska, A., Moles, R., Bissa, M., Sarkis, S., Schifanella, L., Zhou, T., Jones, J., Jacobson, S., & Franchini, G. (2025). Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein. Journal of Virology. https://doi.org/10.1128/jvi.02268-24
Vancouver
Pise-Masison CA, Rahman MA, Masison DC, Gutowska A, Moles R, Bissa M, et al. Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein. Journal of Virology. 2025. doi:10.1128/jvi.02268-24
BibTeX
@article{PiseMasison2025,
author = {Pise-Masison, Cynthia A and Rahman, Mohammad Arif and Masison, Daniel C and Gutowska, Anna and Moles, Ramona and Bissa, Massimiliano and Sarkis, Sarkis and Schifanella, Luca and Zhou, Tongqing and Jones, Jennifer and Jacobson, Steve and Franchini, Genoveffa},
title = {Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein},
journal = {Journal of Virology},
year = {2025},
doi = {10.1128/jvi.02268-24}
}
EUVIMED